Loading…
Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to 9 Years of Treatment
CONTEXT Hydroxyurea increases levels of fetal hemoglobin (HbF) and decreases morbidity from vaso-occlusive complications in patients with sickle cell anemia (SCA). High HbF levels reduce morbidity and mortality. OBJECTIVE To determine whether hydroxyurea attenuates mortality in patients with SCA. DE...
Saved in:
Published in: | JAMA : the journal of the American Medical Association 2003-04, Vol.289 (13), p.1645-1651 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | CONTEXT Hydroxyurea increases levels of fetal hemoglobin (HbF)
and decreases morbidity from vaso-occlusive complications in patients
with sickle cell anemia (SCA). High HbF levels reduce morbidity and
mortality. OBJECTIVE To determine whether hydroxyurea attenuates mortality in
patients with SCA. DESIGN Long-term observational follow-up study of mortality in
patients with SCA who originally participated in the randomized,
double-blind, placebo-controlled Multicenter Study of Hydroxyurea in
Sickle Cell Anemia (MSH), conducted in 1992-1995, to
determine if hydroxyurea reduces vaso-occlusive events. In the MSH
Patients' Follow-up, conducted in 1996-2001, patients could continue,
stop, or start hydroxyurea. Data were collected during the trial and in
the follow-up period. SETTING Inpatients and outpatients in 21 sickle cell referral
centers in the United States and Canada. PATIENTS Two-hundred ninety-nine adult patients with frequent
painful episodes enrolled in the follow-up. Follow-up data through
May 2001 were complete for 233 patients. INTERVENTION In the MSH, patients were randomly assigned to
receive hydroxyurea (n = 152) or placebo (n = 147). MAIN OUTCOME MEASURE Mortality, HbF levels, painful episodes,
acute chest syndrome, and blood cell counts. The randomized trial was
not designed to detect specified differences in mortality. RESULTS Seventy-five of the original 299 patients died, 28% from
pulmonary disease. Patients with reticulocyte counts less than
250 000/mm3 and hemoglobin levels lower than 9 g/dL
had increased mortality (P = .002).
Cumulative mortality at 9 years was 28% when HbF levels were lower
than 0.5 g/dL after the trial was completed compared with 15% when HbF
levels were 0.5 g/dL or higher
(P = .03 ). Individuals who had acute
chest syndrome during the trial had 32% mortality compared with 18%
of individuals without acute chest syndrome
(P = .02). Patients with 3 or more
painful episodes per year during the trial had 27% mortality compared
with 17% of patients with less frequent episodes
(P = .06). Taking hydroxyurea was
associated with a 40% reduction in mortality
(P = .04) in this observational follow-up with
self-selected treatment. There were 3 cases of cancer, 1 fatal. CONCLUSIONS Adult patients taking hydroxyurea for frequent painful
sickle cell episodes appear to have reduced mortality after 9 of years
follow-up. Survival was related to HbF levels and frequency of
vaso-occlusive events. Whether indications for hydroxyurea treatm |
---|---|
ISSN: | 0098-7484 1538-3598 |
DOI: | 10.1001/jama.289.13.1645 |